CLINICAL OUTCOMES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY IN SMALL CELL LUNG CANCER
Keywords:
small cell lung cancer, platinum-based chemotherapy, cisplatin, carboplatin, etoposide, treatment outcomes, toxicity, immunotherapy.Abstract
Small cell lung cancer (SCLC) is one of the most aggressive and rapidly progressing forms of lung malignancy. It accounts for approximately 10–15% of all lung cancer cases worldwide and is characterized by rapid tumor growth, early metastatic spread, high proliferative activity, and poor long-term prognosis. Despite significant advances in cancer therapy, SCLC remains associated with high mortality rates and limited survival outcomes. Platinum-based chemotherapy has remained the cornerstone of first-line treatment for several decades, with cisplatin or carboplatin combined with etoposide representing the standard therapeutic regimen. This review evaluates the clinical outcomes, efficacy, and toxicity profile of platinum-based first-line chemotherapy in patients with SCLC. Data from international clinical guidelines, randomized clinical trials, and recent scientific publications were analyzed. Treatment response rates, overall survival, progression-free survival, and treatment-related adverse events were assessed. The findings indicate that platinum-based chemotherapy achieves high initial response rates ranging from 60% to 80%, with complete responses observed in approximately 20–30% of patients. However, despite favorable initial responses, most patients eventually experience disease recurrence due to the development of therapeutic resistance. Hematological toxicities, including neutropenia, anemia, and thrombocytopenia, as well as non-hematological toxicities such as nephrotoxicity, neuropathy, nausea, and vomiting, remain significant clinical challenges. Recent incorporation of immune checkpoint inhibitors into first-line treatment regimens has demonstrated improvements in overall survival and disease control. Personalized treatment strategies, early toxicity management, and advanced imaging techniques may further improve clinical outcomes and quality of life for patients with SCLC.
References
1. Horn L., Mansfield A.S., Szczęsna A., Havel L., Krzakowski M., Hochmair M.J., et al. (2018). First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 379(23), 2220–2229.
2. Paz-Ares L., Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., et al. (2019). Durvalumab plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial. Lancet, 394(10212), 1929–1939.
3. Rudin C.M., Brambilla E., Faivre-Finn C., Sage J. (2021). Small-Cell Lung Cancer. Nature Reviews Disease Primers, 7(1), 3.
4. Kalemkerian G.P., Schneider B.J. (2024). Advances in Small Cell Lung Cancer. Hematology/Oncology Clinics of North America, 38(2), 205–221.
5. National Comprehensive Cancer Network (NCCN). (2025). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 2.2025.
6. Ettinger D.S., Wood D.E., Aisner D.L., Akerley W., Bauman J.R., Bharat A., et al. (2024). Small Cell Lung Cancer, Version 1.2024, NCCN Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network, 22(1), 1–45.
7. Früh M., De Ruysscher D., Popat S., Crinò L., Peters S., Felip E. (2013). Small-Cell Lung Cancer (SCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology, 24(Suppl. 6), vi99–vi105.
8. van Meerbeeck J.P., Fennell D.A., De Ruysscher D.K. (2011). Small-Cell Lung Cancer. Lancet, 378(9804), 1741–1755.
9. Byers L.A., Rudin C.M. (2015). Small Cell Lung Cancer: Where Do We Go from Here? Cancer, 121(5), 664–672.
10. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. (2006). Changing Epidemiology of Small-Cell Lung Cancer in the United States over the Last 30 Years. Cancer, 107(5), 107–110.
11. Owonikoko T.K., Niu H., Nackaerts K., Csőszi T., Ostoros G., Mark Z., et al. (2021). Randomized Phase III Trial of Cisplatin and Etoposide versus Carboplatin and Etoposide in Small Cell Lung Cancer. Journal of Clinical Oncology, 39(15), 1672–1682.
12. Faivre-Finn C., Snee M., Ashcroft L., Appel W., Barlesi F., Bhatnagar A., et al. (2017). Concurrent Once-Daily versus Twice-Daily Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer (CONVERT): An Open-Label, Phase 3 Trial. Lancet Oncology, 18(8), 1116–1125.
13. Wang S., Zimmermann S., Parikh K., Mansfield A.S., Adjei A.A. (2019). Current Diagnosis and Management of Small-Cell Lung Cancer. Mayo Clinic Proceedings, 94(8), 1599–1622.
14. Sabari J.K., Lok B.H., Laird J.H., Poirier J.T., Rudin C.M. (2017). Unravelling the Biology of SCLC: Implications for Therapy. Nature Reviews Clinical Oncology, 14(9), 549–561.
15. Dingemans A.C., Früh M., Ardizzoni A., Besse B., Faivre-Finn C., Hendriks L.E., et al. (2021). Small-Cell Lung Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. Annals of Oncology, 32(7), 839–853.